Research and innovation in cloud in the pharmaceutical sector has stagnated in the last quarter.
The most recent figures show that the number of related patent applications in the industry stood at 18 in the three months ending February – the same as 18 over the same period in 2021.
Figures for patent grants related to followed a different pattern to filings – shrinking from seven in the three months ending February 2021 to two in the same period in 2022.
The figures are compiled by GlobalData, who track patent filings and grants from official offices around the world. Using textual analysis, as well as official patent classifications, these patents are grouped into key thematic areas, and linked to key companies across various industries.
Cloud innovation is one of the key areas tracked by GlobalData. It has been identified as being a key disruptive force facing companies in the coming years, and is one of the areas that companies investing resources in now are expected to reap rewards from.
The figures also provide an insight into the largest innovators in the sector.
Pfizer Inc was the top innovator in the pharmaceutical sector in the latest quarter. The company, which has its headquarters in the United States, filed 22 related patents in the three months ending February. That was up from 12 over the same period in 2021.
It was followed by the United States based Johnson & Johnson with nine patent applications, Germany based Bayer AG (6 applications), and Switzerland based Ypsomed Holding AG (2 applications).
Pfizer Inc has recently ramped up R&D in . It saw growth of 45.5% in related patent applications in the three months ending February compared to the same period in 2021 - the highest percentage growth out of all companies tracked with more than 10 quarterly patents in the pharmaceutical sector.